Fig. 1: PFS.

PFS in the (A) fit, intermediate, and frail subgroups and (B) total–non-frail and frail subgroups. PFS progression-free survival, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval.